Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report
Po‐Lan Su, Chien‐Yu Lin, Yilin Chen, Wanli Chen, Chien‐Chung Lin, Wu‐Chou Su
Abstract
Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with NSCLC with a BRAF V600E mutation. Nevertheless, the treatment strategy for patients with NSCLC with BRAF non-V600E mutations remains limited. Here, we present a patient with NSCLC with a BRAF K601E mutation, a class II BRAF mutation, who had a durable response to targeted therapy with combined dabrafenib and trametinib.
Topics & Concepts
DabrafenibTrametinibMedicineMutationAdenocarcinomaOncologyV600ELung cancerCancer researchTargeted therapyMEK inhibitorInternal medicineVemurafenibMAPK/ERK pathwayMelanomaCancerBiologyKinaseGeneGeneticsMetastatic melanomaMelanoma and MAPK PathwaysLung Cancer Treatments and MutationsSynthesis and biological activity